Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have received an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $7.5714.

HUMA has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Humacyte in a research note on Tuesday. Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Tuesday, April 28th. BTIG Research lowered their target price on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research note on Friday, April 10th.

Humacyte Trading Up 3.6%

HUMA stock opened at $1.15 on Thursday. The company’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $1.03. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. Humacyte has a 52-week low of $0.55 and a 52-week high of $2.93. The firm has a market cap of $255.32 million, a P/E ratio of -2.02 and a beta of 2.31.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. The business had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.46 million. As a group, equities analysts forecast that Humacyte will post -0.32 EPS for the current fiscal year.

Insider Transactions at Humacyte

In related news, CFO Dale A. Sander sold 45,887 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the transaction, the chief financial officer directly owned 267,213 shares of the company’s stock, valued at approximately $240,491.70. This trade represents a 14.66% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shamik J. Parikh sold 45,887 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the transaction, the insider directly owned 272,713 shares in the company, valued at $245,441.70. This represents a 14.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Sei Investments Co. purchased a new position in Humacyte in the 1st quarter valued at about $56,000. R Squared Ltd lifted its stake in Humacyte by 140.5% in the 1st quarter. R Squared Ltd now owns 62,911 shares of the company’s stock valued at $38,000 after buying an additional 36,758 shares in the last quarter. Private Advisor Group LLC lifted its stake in Humacyte by 48.3% in the 1st quarter. Private Advisor Group LLC now owns 832,799 shares of the company’s stock valued at $505,000 after buying an additional 271,222 shares in the last quarter. Wealth Effects LLC lifted its stake in Humacyte by 33.6% in the 1st quarter. Wealth Effects LLC now owns 204,500 shares of the company’s stock valued at $124,000 after buying an additional 51,433 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Humacyte by 841.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock valued at $68,000 after buying an additional 62,931 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.